| Drug Name: | Valnoctamide (4171-13-5) |
|---|---|
| PubChem ID: | 20140 |
| SMILES: | CCC(C)C(CC)C(=O)N |
| InchiKey: | QRCJOCOSPZMDJY-UHFFFAOYSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 143.23 |
| LogP | : | 1.544 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 1 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 43.09 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Carbamazepine (298-46-4) | Nystagmus | Synergistic | Valnoctamide inhibits the enzyme epoxide hydrolase, which is concerned with the metabolism and elimination of carbamazepine and its active epoxide metabolite | Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category
| Toxicity | Source |
|---|